A modular mRNA vaccine platform encoding antigen-presenting capsid virus-like particles enhances the immunogenicity of the malaria antigen Pfs25
Source abstract
Abstract
The COVID-19 pandemic has emphasized the potential of mRNA vaccines in fighting pandemics, owing to their rapid development, strong immunogenicity and adaptability. However, a drawback is their dose-limiting reactogenicity and inability to generate durable humoral immunity. Here we introduce a modular nucleotide vaccine platform combining the advantages of genetic and capsid virus-like-particle-based vaccines. This platform allows for the display of various antigens on different capsid virus-like particles, improving the magnitude, quality and longevity of the vaccine-induced immune responses. We applied this technology to enhance the immunogenicity of the Pfs25 antigen. Immunization with lipid-nanoparticle-formulated mRNA encoding Pfs25 capsid virus-like particles resulted in higher and potentially more durable anti-Pfs25 antibody responses, along with enhanced functional activity, compared with an mRNA vaccine encoding soluble Pfs25. By improving both humoral and cellular immune responses, this approach may reduce the dose and number of administrations required for effective protection. As a result, it can improve the feasibility of both DNA- and mRNA-based vaccines targeting pandemic and endemic infectious diseases.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: vaccines and immunoinformatics approaches · Monoclonal and Polyclonal Antibodies Research · Bacteriophages and microbial interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (58)
Show source-provided references
1. CEPI. CEPI Strategy for the Second Business Cycle 2022–2026 (CEPI, 2021); https://static.cepi.net/downloads/2023-12/CEPI-2022-2026-Strategy-v3-Jan21_0.pdf
2. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).10.1056/NEJMoa2034577 ↗
3. Lee, I. T. et al. Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat. Commun. 14, 3631 (2023).10.1038/s41467-023-39376-7 ↗
4. Naaber, P. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg. Health Eur. 10, 100208 (2021).10.1016/j.lanepe.2021.100208 ↗
5. Pegu, A. et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science 373, 1372–1377 (2021).10.1126/science.abj4176 ↗
6. Soucheray, S. Moderna reports RSV vaccine 50% effective after 18 months (2024); https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/moderna-reports-rsv-vaccine-50-effective-after-18-months
7. Lee, J., Woodruff, M. C., Kim, E. H. & Nam, J.-H. Knife’s edge: balancing immunogenicity and reactogenicity in mRNA vaccines. Exp. Mol. Med. 55, 1305–1313 (2023).10.1038/s12276-023-00999-x ↗
8. Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589–593 (2020).10.1038/s41586-020-2639-4 ↗
9. Basu, P. et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 22, 1518–1529 (2021).10.1016/S1470-2045(21)00453-8 ↗
10. Slifka, M. K. & Amanna, I. J. Role of multivalency and antigenic threshold in generating protective antibody responses. Front. Immunol. 10, 956 (2019).10.3389/fimmu.2019.00956 ↗
11. Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903–1915 (2007).10.1056/NEJMoa066092 ↗
12. Bhattacharya, D. Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. Immunity 55, 945–964 (2022).10.1016/j.immuni.2022.05.004 ↗
13. Bachmann, M. F. et al. The influence of antigen organization on B cell responsiveness. Science 262, 1448–1451 (1993).10.1126/science.8248784 ↗
14. Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787–796 (2010).10.1038/nri2868 ↗
15. Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl Acad. Sci. USA 109, E690–E697 (2012).10.1073/pnas.1115485109 ↗
16. Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367–1382.e17 (2020).10.1016/j.cell.2020.10.043 ↗
17. Fougeroux, C. et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nat. Commun. 12, 324 (2021).10.1038/s41467-020-20251-8 ↗
18. Thrane, S. et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J. Nanobiotechnol. 14, 30 (2016).10.1186/s12951-016-0181-1 ↗
19. Smit, M. J. et al. First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2. Lancet Microbe 4, e140–e148 (2023).10.1016/S2666-5247(22)00337-8 ↗
20. Tursi, N. J., Xu, Z., Kulp, D. W. & Weiner, D. B. Gene-encoded nanoparticle vaccine platforms for in vivo assembly of multimeric antigen to promote adaptive immunity. WIREs Nanomed. Nanobiotechnol. 15, e1880 (2023).10.1002/wnan.1880 ↗
21. Lu, J. et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 30, 936–939 (2020).10.1038/s41422-020-00392-7 ↗
22. Sun, W. et al. The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. Signal Transduct. Target. Ther. 6, 340 (2021).10.1038/s41392-021-00750-w ↗
23. Brandys, P. et al. A mRNA vaccine encoding for a RBD 60-mer nanoparticle elicits neutralizing antibodies and protective immunity against the SARS-CoV-2 Delta variant in transgenic K18-hACE2 mice. Front. Immunol. 13, 912898 (2022).10.3389/fimmu.2022.912898 ↗
24. Chackerian, B. Virus-like particles: flexible platforms for vaccine development. Expert Rev. Vaccines 6, 381–390 (2007).10.1586/14760584.6.3.381 ↗
25. Hoffmann, M. A. G. et al. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines. Cell 186, 2380–2391.e9 (2023).10.1016/j.cell.2023.04.024 ↗
26. Mendy, M. et al. Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS ONE 8, e58029 (2013).10.1371/journal.pone.0058029 ↗
27. Valéa, I. et al. Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: a randomized controlled trial. Hum. Vaccines Immunother. 14, 1489–1500 (2018).10.1080/21645515.2018.1442996 ↗
28. Schiller, J. & Lowy, D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine 36, 4768–4773 (2018).10.1016/j.vaccine.2017.12.079 ↗
29. Sagara, I. et al. Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial. Lancet Infect. Dis. 23, 1266–1279 (2023).10.1016/S1473-3099(23)00276-1 ↗
30. Bruun, T. U. J., Andersson, A.-M. C., Draper, S. J. & Howarth, M. Engineering a rugged nanoscaffold to enhance plug-and-display vaccination. ACS Nano 12, 8855–8866 (2018).10.1021/acsnano.8b02805 ↗
31. Rahikainen, R. et al. Overcoming symmetry mismatch in vaccine nanoassembly through spontaneous amidation. Angew. Chem. Int. Ed. 60, 321–330 (2021).10.1002/anie.202009663 ↗
32. Kumar, S., Sunagar, R. & Gosselin, E. Bacterial protein toll-like-receptor agonists: a novel perspective on vaccine adjuvants. Front. Immunol. 10, 1144 (2019).10.3389/fimmu.2019.01144 ↗
33. Wang, J. Y. J. et al. Improving the secretion of designed protein assemblies through negative design of cryptic transmembrane domains. Proc. Natl Acad. Sci. USA 120, e2214556120 (2023).10.1073/pnas.2214556120 ↗
34. Silveira, M. M., Moreira, G. M. S. G. & Mendonça, M. DNA vaccines against COVID-19: perspectives and challenges. Life Sci. 267, 118919 (2021).10.1016/j.lfs.2020.118919 ↗
35. Maslow, J. N. et al. DNA vaccines for epidemic preparedness: SARS-CoV-2 and beyond. Vaccines 11, 1016 (2023).10.3390/vaccines11061016 ↗
36. Khobragade, A. et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet 399, 1313–1321 (2022).10.1016/S0140-6736(22)00151-9 ↗
37. Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187–2201 (2021).10.1056/NEJMoa2101544 ↗
38. Andrade, V. M. et al. Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models. Hum. Vaccines Immunother. 19, 2281733 (2023).10.1080/21645515.2023.2281733 ↗
39. Woldemeskel, B. A., Garliss, C. C. & Blankson, J. N. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. J. Clin. Invest. 131, e149335 (2021).10.1172/JCI149335 ↗
40. Freyn, A. W. et al. Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice. Mol. Ther. Methods Clin. Dev. 22, 84–95 (2021).10.1016/j.omtm.2021.06.003 ↗
41. Melzi, E. et al. Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice. Immunity 55, 2168–2186.e6 (2022).10.1016/j.immuni.2022.09.003 ↗
42. Hendricks, G. G. et al. Computationally designed mRNA-launched protein nanoparticle vaccines. Immunity 55, 2168–2186.e6 (2024).10.1101/2024.07.22.604655 ↗
43. Israel, A. et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. Brit. Med. J. 375, e067873 (2021).10.1136/bmj-2021-067873 ↗
44. Sudharsanan, N., Favaretti, C., Hachaturyan, V., Bärnighausen, T. & Vandormael, A. Effects of side-effect risk framing strategies on COVID-19 vaccine intentions: a randomized controlled trial. eLife 11, e78765 (2022).10.7554/eLife.78765 ↗
45. Kjaer, S. K. et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. eClinicalMedicine 23, 100401 (2020).10.1016/j.eclinm.2020.100401 ↗
46. Nguyen, D. C. et al. SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination. Nat. Med. 31, 235–244 (2024).10.1038/s41591-024-03278-y ↗
47. Bloom, K., van den Berg, F. & Arbuthnot, P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 28, 117–129 (2021).10.1038/s41434-020-00204-y ↗
48. Maruggi, G., Ulmer, J. B., Rappuoli, R. & Yu, D. Self-amplifying mRNA-based vaccine technology and its mode of action. Curr. Topics Microbiol. Immunol. 440, 31–70 (2022).
49. Swetha, K. et al. Recent advances in the lipid nanoparticle-mediated delivery of mRNA vaccines. Vaccines 11, 658 (2023).10.3390/vaccines11030658 ↗
50. Ross, J. & Sullivan, T. D. Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes. Blood 66, 1149–1154 (1985).10.1182/blood.V66.5.1149.1149 ↗
51. Gallie, D. R. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev. 5, 2108–2116 (1991).10.1101/gad.5.11.2108 ↗
52. Karikó, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008).10.1038/mt.2008.200 ↗
53. Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 23, 1456–1464 (2015).10.1038/mt.2015.103 ↗
54. Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864–1869 (2010).10.1073/pnas.0910603106 ↗
55. Aljabbari, A. et al. Elucidating the nanostructure of small interfering RNA-loaded lipidoid-polymer hybrid nanoparticles. J. Colloid Interface Sci. 633, 907–922 (2023).10.1016/j.jcis.2022.11.141 ↗
56. Ponnudurai, T. et al. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology 98, 165–173 (1989).10.1017/S0031182000062065 ↗
57. Ramjith, J. et al. Quantifying reductions in Plasmodium falciparum infectivity to mosquitos: a sample size calculator to inform clinical trials on transmission-reducing interventions. Front. Immunol. 13, 899615 (2022).10.3389/fimmu.2022.899615 ↗
58. McLeod, B. et al. Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses. Immunity 55, 1680–1692.e8 (2022).10.1016/j.immuni.2022.07.015 ↗